Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Brent McKenzie - Senior Director Translational Immunology, Translational Immunology

Brent McKenzie

Senior Director Translational Immunology, Translational Immunology

"In gRED we share a passion to translate the biggest scientific advances of today into the best possible drugs of tomorrow."
Years at Genentech
Awards & Honors

I joined gRED in 2014 to lead the Translational Immunology department and find the research environment at Genentech incredibly rewarding. I enjoy the challenge of working across multiple areas of unmet medical need alongside some of the best and brightest scientists. I was drawn to industry research early in my career through a fruitful collaboration as a PhD student in the Autoimmunity and Transplantation department at the Walter and Eliza Hall Institute (WEHI). After a postdoc I moved from WEHI to DNAX in Palo Alto California (now Merck) to further my experience in early stage drug discovery. There we performed pioneering work on cytokine and T cell biology that underpins several new drug targets still being pursued today. I then joined CSL ltd in Parkville Australia where I continued to employ numerous in-vivo models to understand cellular and subcellular mechanisms of Autoimmunity, Inflammation, Fibrosis, Coagulation, Cancer, Metabolism & Vaccine responses.

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Cell Death Differ. 2016 Sep 1;23(9):1565-76.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.